FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers
FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers Print this page November 26, 2018 — The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker). This is the second time the agency has approved a cancer treatment… Read More »